• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    2
    JULY SPECIAL! 21 Blend Combo Sampler (Save 55%) $1740 value for $777! Comes with Interstellar Mug!
    March 30, 2019
    Peel & Spice Combo 200:1
    July 1, 2019

    LUTEOLIN 200:1

    Rated 5.00 out of 5 based on 13 customer ratings
    (13 customer reviews)

    $250.00

    Clear
    SKU: N/A Categories: Exclusive Products, Featured
    Share
    0
    • Description
    • Reviews (13)


    LUTEOLIN

    Top candidates at fighting coronoavirus: LUTEOLIN. 



    Cytotoxic inhibitors of Hsp90 are the ONLY cancer chemotherapeutic agents known to impact all six hallmarks of cancer simultaneously. As defined by Hanahan and Weinberg, this includes:
    1) self-sufficiency in growth signals,
    2) insensitivity to antigrowth signals,
    3) evasion of apoptosis,
    4) limitless replicative potential,
    5) sustained angiogenesis, and
    6) tissue invasion/metastasis.

    *This study indicated that LUTEOLIN may act as a potent HSP90 inhibitor in antitumor strategies.

     

    1. Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury
    2. PEA and Luteolin synergistically reduce mast cell-mediated toxicityand elicit neuroprotection in cell-based models of brain ischemia
    3. Neuroprotection of LuteolinAgainst Aβ_(25-35) Induced Neural Damage
    4. Luteolin downregulates TLR4, TLR5, NF-κB and p-p38MAPK expression, upregulates the p-ERK expression, and protects rat brains against focal ischemia
    5. Luteolin reduced the traumatic brain injury-induced memory impairments in rats: Attenuating oxidative stress and dark neurons of Hippocampus
    6. Ameliorating effect of Luteolin on memory impairment in an Alzheimer’s disease model
    7. Erratum to: A new co-ultramicronized composite including palmitoylethanolamide and Luteolin to prevent neuroinflammation in spinal cord injury
    8. The effects of C-glycosylation of Luteolin on its antioxidant, anti-Alzheimer’s disease, anti-diabetic, and anti-inflammatory activities
    9. Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
    10. Simultaneous electroanalytical determination of Luteolin and rutin using artificial neural networks
    11. Luteolin as a potential preventive and therapeutic candidate for Alzheimer’s disease
    12. Luteolin Exerts Neuroprotective Effect by Up-regulation of HO-1 via JNK Pathway in Primary Cultured Rat Cortical Cells
    13. Postischemic administration of liposome-encapsulated Luteolin prevents against ischemia-reperfusion injury in a rat middle cerebral arteryocclusion model
    14. Neurotrophic and Cytoprotective Action of Luteolin in PC12 Cells through ERK-Dependent Induction of Nrf2-Driven HO-1 Expression
    15. Neuroprotective effect of Luteolin on amyloid β protein (25–35)‐induced toxicity in cultured rat cortical neurons
    16. Brain Inflammation, Neuropsychiatric Disorders, and Immunoendocrine Effects of Luteolin
    17. Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats
    18. Protective role of Luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats
    19. Luteolin as an anti-inflammatory and neuroprotective agent: A brief review
    20. Protective effects of Luteolin against cognitive impairment induced by infusion of Aβ peptide in rats
    21. The anti-amnesic effects of Luteolin against amyloid β25–35 peptide-induced toxicity in mice involve the protection of neurovascular unit
    22. Luteolin protects against high fat diet-induced cognitive deficits in obesity mice
    23. Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons
    24. Pharmacodynamic Effect of Luteolin Micelles on Alleviating Cerebral Ischemia Reperfusion Injury
    25. Luteolin Reduces Zinc-Induced Tau Phosphorylation at Ser262/356 in an ROS-Dependent Manner in SH-SY5Y Cells
    26. Dietary Luteolin Reduces Proinflammatory Microglia in the Brain of Senescent Mice
    27. Effects of Luteolin onlearning acquisition in rats: Involvement of the central cholinergic system
    28. Luteolin Inhibits Microglial Inflammation and Improves Neuron Survival Against Inflammation
    29. Luteolin reduces primary hippocampal neurons death induced by neuroinflammation
    30. Luteolin improves the impaired nerve functions in diabetic neuropathy: behavioral and biochemical evidences
    31. Neuroprotective effects of Luteolin against apoptosis induced by 6-hydroxydopamine on rat pheochromocytoma PC12 cells
    32. Luteolin Inhibits Microglia and Alters Hippocampal-Dependent Spatial Working Memory in Aged Mice
    33. Luteolin protects the hippocampus against neuron impairments induced by kainic acid in rats
    34. Protective properties of quercetin and Luteolin from Petasites japonicus leaves against Aβ (25–35)-induced neurotoxicity in B103 cells
    35. Therapeutic potential of Luteolin in transgenic Drosophila model of Alzheimer’s disease
    36. Luteolin Could Improve Cognitive Dysfunction by Inhibiting Neuroinflammation
    37. Cellular uptake of quercetin and Luteolin and their effects on monoamine oxidase-A in human neuroblastoma SH-SY5Y cells
    38. Luteolin attenuates neuronal apoptosis in the hippocampi of diabetic encephalopathy rats
    39. The protective effect of Luteolin on amyloid β protein (25–35)-induced neurotoxicity in primary rat cortical neuron cells and possible mechanisms
    40. Additive Protective Effects of Luteolin and Pyruvate against 6-Hydroxydopamine and 3-Hydroxykynurenine Induced Neurotoxicity in SH-SY5Y Cells
    41. Bioavailability and Pharmaco-therapeutic Potential of Luteolin in Overcoming Alzheimer’s Disease
    42. A new therapeutic target for Alzheimer’s disease: effects of palmitoylethanolamide with Luteolin association on neuroinflammation pathway (845.10)
    43. The combination of Luteolin and l-theanine improved Alzheimer disease–like symptoms by potentiating hippocampal insulin signaling and decreasing neuroinflammation and norepinephrine degradation in amyloid-β–infused rats
    44. Luteolin provides neuroprotection in models of traumatic brain injury via the Nrf2–ARE pathway
    45. Effects of intrathecal and intracerebroventricular administration of Luteolin in a rat neuropathic pain model
    46. Effects of Luteolinon spatial memory, cell proliferation, and neuroblast differentiation in the hippocampal dentate gyrus in a scopolamine-induced amnesia model
    47. Neuroprotection ofLuteolin against methylmercury-induced toxicity in lobster cockroach Nauphoeta cinerea
    48. Luteolin induces hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome
    49. Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury
    50. Luteolin Protected against Beta-Amyloid-induced Neuronal Cell Death and Memory Impairment via Activation of Nrf2-HO-1 Signaling Pathway
    51. A new co-ultramicronized composite including palmitoylethanolamide and Luteolin to prevent neuroinflammation in spinal cord injury
    52. Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
    53. Sa1967 The Effect of Flavonoids Luteolin and Quercetin Upon Colon Cancer Cells In Vitro; “So What’s in Your Fiber?”
    54. Protective role of Luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis
    55. Anti-tumor promoting potential of Luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats
    56. Dose- and Time-Dependent Effects of Luteolin on Liver Metallothioneins and Metals in Carbon Tetrachloride-Induced Hepatotoxicity in Mice
    57. Luteolin reduces cancer‑induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model
    58. Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I
    59. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells
    60. Luteolin Induces Apoptosis in Oral Squamous Cancer Cells
    61. Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ β-catenin pathway
    62. The Effect of Luteolin on Lymphocyte Cells In Leukemia Patient
    63. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound Luteolin
    64. Luteolin Inhibits Protein Kinase Cε and c-Src Activities and UVB-Induced Skin Cancer
    65. Anti-carcinogenic Effects of the Flavonoid Luteolin
    66. Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells
    67. The combination of TRAIL and Luteolin enhances apoptosis in human cervical cancer HeLa cells
    68. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin
    69. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid Luteolin in human epithelioid cancer cells
    70. Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells
    71. A Critical Role of Luteolin-Induced Reactive Oxygen Species in Blockage of Tumor Necrosis Factor-Activated Nuclear Factor-κB Pathway and Sensitization of Apoptosis in Lung Cancer Cells
    72. Cytochrome P450 CYP1 metabolism of hydroxylated flavones and flavonols: Selective bioactivation of Luteolin in breast cancer cells.
    73. Anti-cancer Effects of Luteolin and Its Novel Mechanism in HepG2 Hepatocarcinoma Cell
    74. Luteolin, a novel natural inhibitor of TPL2 kinase, inhibits tumor necrosis factor-α-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells
    75. Anti-tumor mechanisms of Luteolin, a major Flavonoid oF Chrysanthemum Morifolium
    76. Luteolin Suppresses Proliferation of Choriocarcinoma Cells through Regulating PI3K/AKT Signaling Pathway and Blocking Transcriptional Activity of SREBP1
    77. Anti-proliferative and chemosensitizing effects of Luteolin on human gastric cancer AGS cell line
    78. Sensitizing HER2-overexpressing cancer cellsto Luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin
    79. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells
    80. Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: a review.
    81. Synergistic apoptotic effect of celecoxib and Luteolin on breast cancer cells
    82. Molecular targets of Luteolin in cancer
    83. Luteolin Induces Growth Arrest in Colon Cancer Cells Through Involvement of Wnt/β-Catenin/GSK-3β Signaling
    84. Characteristic rat tissue accumulation of nobiletin, a chemopreventive polymethoxyflavonoid, in comparison with Luteolin
    85. Luteolin Inhibits Proliferation Induced by IGF-1 Pathway Dependent ERα in Human Breast Cancer MCF-7 Cells
    86. Effects of dietary flavonoids, Luteolin, and quercetin on the reversal of epithelial–mesenchymal transition in A431 epidermal cancer cells
    87. Luteolin attenuates TGF-β1-induced epithelial–mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt–NF-κB–Snail pathway
    88. Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3
    89. The dietary flavonoid Luteolin inhibits Aurora B kinase activity and blocks proliferation of cancer cells
    90. Serum Concentration of Genistein, Luteolin and Colorectal Cancer Prognosis
    91. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    92. Cancer Chemopreventive Potential of Luteolin-7-O-Glucoside Isolated From Ophiorrh
    93. Proteomic identification of anti-cancer proteins in Luteolin-treated human hepatoma Huh-7 cells
    94. Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through activation of Nrf2 signaling
    95. Luteolin suppresses growth and migration of human lung cancer cells
    96. Response of Myeloid Leukemia Cells to Luteolin is Modulated by Differentially Expressed Pituitary Tumor-Transforming Gene 1 (PTTG1) Oncoprotein
    97. Luteolininduces apoptosis in multidrug resistant cancer cellswithout affecting the drug transporter function: Involvement of cell line‐specific apoptotic mechanisms
    98. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis
    99. Luteolin Inhibits Breast Cancer Development and Progression In Vitro and In Vivo by Suppressing Notch Signaling and Regulating MiRNAs
    100. Luteolin inhibits Musashi1 binding to RNA and disrupts cancer phenotypes in glioblastoma cells
    101. Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells
    102. Combination of oncolytic adenovirus and Luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model
    103. Targeted Luteolin Delivery via Bevacizumab-Modified Polymer Microbubbles to Colon Cancer Cells
    104. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer
    105. Luteolin enhances TNF-related apoptosis-inducing ligand’s anticancer activity in a lung cancer xenograft mouse model
    106. Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells
    107. Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells
    108. Luteolin induces apoptotic cell death through AIF nuclear translocation mediated by activation of ERK and p38 in human breast cancer cell lines
    109. Radiosensitization effect of Luteolin on human gastric cancer SGC-7901 cells.
    110. Extra precision Docking studies of novel Luteolin analogues for the inhibition of Tankyrase II- “a theoretical based approach towards novel cancer target
    111. The Influence of Luteolin on Schultz-Dale Response in Animals
    112. Luteolin Attenuates Doxorubicin-Induced Cytotoxicity to MCF-7 Human Breast Cancer Cells
    113. Gefitinib and Luteolin Cause Growth Arrest of Human Prostate Cancer PC-3 Cells via Inhibition of Cyclin G-Associated Kinase and Induction of miR-630
    114. Luteolin Induces Apoptosis by Up-regulating miR-34a in Human Gastric Cancer Cells
    115. Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression
    116. Luteolin 8-C-β-fucopyranoside inhibits invasion and suppresses TPA-induced MMP-9 and IL-8 via ERK/AP-1 and ERK/NF-κB signaling in MCF-7 breast cancer cells
    117. Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts
    118. Inhibition of hypoxia-induced epithelial mesenchymal transition by Luteolin in non-small cell lung cancer cells
    119. Luteolin Suppresses Cancer Cell Proliferation by Targeting Vaccinia-Related Kinase 1
    120. EBV reactivation as a target of Luteolin to repress NPC tumorigenesis
    121. Luteolin Induces Cell Cycle Arrest and Apoptosis Through Extrinsic and Intrinsic Signaling Pathways in MCF-7 Breast Cancer Cells
    122. Luteolin is effective in thenon-small cell lung cancer model with L858R/T790MEGF receptor mutation anderlotinib resistance
    123. Molecular mechanisms of Luteolin-7-O-glucoside-induced growth inhibition on human liver cancer cells: G2/M cell cycle arrest and caspase-independent apoptotic signaling pathways
    124. Breast Cancer Resistance Protein-Mediated Efflux of Luteolin Glucuronides in HeLa Cells Overexpressing UDP-Glucuronosyltransferase 1A9
    125. Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells
    126. Proteomic analysis reveals ATP-dependent steps and chaperones involvement in Luteolin–induced lung cancer CH27 cell apoptosis
    127. Epithelial‐to‐Mesenchymal Transition in Paclitaxel‐Resistant Ovarian Cancer Cells Is Downregulated by Luteolin
    128. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells
    129. Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells
    130. [Effect of Luteolin and its combination with chemotherapeutic drugs on cytotoxicity of cancer cells].
    131. Luteolin Impacts on the DNA Damage Pathway in Oral Squamous Cell Carcinoma
    132. Luteolin: Anti-breast Cancer Effects and Mechanisms
    133. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cellsthrough miR-301
    134. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
    135. A Superoxide-Mediated Mitogen-Activated Protein Kinase Phosphatase-1 Degradation and c-Jun NH2-Terminal Kinase Activation Pathway for Luteolin–Induced Lung Cancer Cytotoxicity
    136. Sphingosine Kinase 2 and Ceramide Transport as Key Targets of the Natural Flavonoid Luteolin to Induce Apoptosis in Colon Cancer Cells
    137. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis
    138. Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1
    139. Synergistic effect between celecoxib and Luteolin is dependent on estrogen receptor in human breast cancer cells
    140. Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer
    141. Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade
    142. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with Luteolin
    143. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression
    144. Attenuating Smac mimetic compound 3‐induced NF‐κB activation by Luteolin leads to synergistic cytotoxicity in cancer cells
    145. Luteolin Induces Apoptosis in BE Colorectal Cancer Cells by Downregulating Calpain, UHRF1, and DNMT1 Expressions
    146. Inhibitory effect of Luteolin on the proliferation of human breast cancer cell lines induced by epidermal growth factor.
    147. Luteolin induces N-acetylation and DNA adduct of 2-aminofluorene accompanying N-acetyltransferase activity and gene expression in human bladder cancer T24 cell line.
    148. Inhibition of ANO1 by Luteolin and its cytotoxicity in human prostate cancer PC-3 cells
    149. Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer
    150. Anti-tumor effect of Luteolin is accompanied by AMP-activated protein kinase and nuclear factor-κB modulation in HepG2 hepatocarcinoma cells
    151. Cytochrome P450 CYP1 metabolism of hydroxylated flavones and flavonols: Selective bioactivation of Luteolin in breast cancer cells
    152. Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway.
    153. Luteolin Overcomes Resistance to Benzyl Isothiocyanate- Induced Apoptosis in Human Colorectal Cancer HCT-116 Cells
    154. Main components of pomegranate, ellagic acid and Luteolin, inhibit metastasis of ovarian cancerby down-regulating MMP2 and MMP9
    155. Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway
    156. Inhibition of the metastatic progression of breast and colorectal cancer in vitro and in vivo in murine model by the oxidovanadium(IV) complex with Luteolin
    157. Modulatory effect of Luteolin on redox homeostasis and inflammatory cytokines in a mouse model of liver cancer
    158. Dietary flavonoids, Luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial–mesenchymal transition signaling
    159. Mechanism of metastasis suppression by Luteolin in breast cancer
    160. Luteolin induces apoptosis in mouse liver cancer cells through ROS mediatedpathway: A mechanistic investigation.
    161. Kaempherol and Luteolin Decrease Claudin-2 Expression Mediated by Inhibition of STAT3 in Lung Adenocarcinoma A549 Cells
    162. Anticancer effect of Luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells
    163. RPS12 increases the invasiveness in cervical cancer activatedby c-Myc and inhibited by the dietary flavonoids Luteolin and quercetin
    164. Luteolin inhibits colorectal cancer cell epithelial-to-mesenchymal transition by suppressing CREB1 expression revealed by comparative proteomics study
    165. Luteolin sensitizes human liver cancer cells to TRAIL‑induced apoptosis via autophagy and JNK‑mediated death receptor 5 upregulation
    166. Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction
    167. [Inhibitory effect of Luteolin on the angiogenesis of chick chorioallantoic membrane and invasion of breast cancer cells via downregulation of AEG-1 and MMP-2].
    168. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p
    169. [Research progress on anti-tumor effects of Luteolin].
    170. Luteolin prevents UV-induced skin damage and MMP-1 activation by interfering with the P38-MAPK pathway and IL-20 release
    171. Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model.
    172. Luteolin-Loaded Spion as a Drug Carrier for Cancer Cell In Vitro
    173. Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancerstemness revealed by comparative proteomics
    174. MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to Luteolin by directly targeting HK1
    175. Apigenin and Luteolin Attenuate the Breaching of MDA-MB231 Breast Cancer Spheroids Through the Lymph Endothelial Barrier in Vitro
    176. Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells
    177. Consumption of the Dietary Flavonoids Quercetin, Luteolin and Kaempferol and Overall Risk of Cancer– A Review and Meta-Analysis of the Epidemiological Data
    178. Cuminum cyminum fruits as source of Luteolin-7-O-glucoside, potent cytotoxic flavonoid against breast cancer cell lines
    179. Luteolin exerts pro-apoptotic effect and anti-migration effects on A549 lung adenocarcinoma cellsthrough the activation of MEK/ERK signaling pathway
    180. Effects of Luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells.
    181. Effects of Luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis‐associated properties in A431 cells overexpressing epidermal growth factor receptor
    182. Inhibitory effect of Luteolin on hepatocyte growth factor/scatter factor–induced HepG2 cell invasion involving both MAPK/ERKs and PI3K–Akt pathways
    183. Protective effect of quercetin and Luteolin in human melanoma HMB-2 cells
    184. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo
    185. Enhanced Anti-tumor Activity by the Combination of the Natural Compounds (−)-Epigallocatechin-3-gallate and Luteolin
    186. Protective role of Luteolin in 1,2‐dimethylhydrazine induced experimental colon carcinogenesis
    187. Luteolin prevents PDGF-BB-induced proliferation of vascular smooth muscle cellsby inhibition of PDGF β-receptor phosphorylation
    188. Luteolin Inhibits Human Prostate Tumor Growthby Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis
    189. Chemoprotective effect of plant phenolics against anthracycline‐induced toxicity on rat cardiomyocytes. Part III. Apigenin, baicalelin, kaempherol, Luteolin and quercetin
    190. Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase–mediated p53 phosphorylation and stabilization
    191. Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt–GSK-3β–Cyclin D1 pathway
    192. Whitening activity of Luteolin related to the inhibition of cAMP pathway in α-MSH-stimulated B16 melanoma cells
    193. Chemopreventive potential of Luteolin during colon carcinogenesis induced by 1,2-dimethylhydrazine.
    194. Luteolin Nanoparticle in Chemoprevention: In Vitro and In Vivo Anticancer Activity
    195. Inhibitory effects of Luteolin isolated fromixeris sonchifolia hance on the proliferation of hepg2 human hepatocellular carcinoma cells
    196. Protective effects of Luteolin-7-glucoside against liver injury caused by carbon tetrachloride in rats
    197. Effect of Luteolin on the Levels of Glycoproteins During Azoxymethane-induced Colon Carcinogenesis in Mice
    198. Autophagy Inhibitor ChloroquineEnhanced the Cell Death Inducing Effect of the Flavonoid Luteolin in Metastatic Squamous Cell Carcinoma Cells
    199. Upregulation of prostate‐derived Ets factor by Luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells
    200. Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis
    201. Luteolin-loaded Phytosomes Sensitize Human Breast CarcinomaMDA-MB 231 Cells to Doxorubicin by Suppressing Nrf2 Mediated Signalling
    202. Luteolin reduces the invasive potential ofmalignant melanoma cells by targeting β3 integrin and the epithelial-mesenchymal transition
    203. The flavonoids diosmetin and Luteolinexert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation
    204. Luteolin–inhibited arylamine N-acetyltransferase activity and DNA–2-aminofluorene adduct in human and mouse leukemia cells
    205. Luteolin modulates expression of drug-metabolizing enzymes through the AhR and Nrf2 pathways in hepatic cells
    206. Luteolin enhances cholinergic activities in PC12 cells through ERK1/2 and PI3K/Akt pathways
    207. Luteolin, a flavonoid, as an anticancer agent: A review
    208. Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR‑384/pleiotrophin axis
    209. Apoptosis induced by Luteolin in breast cancer: Mechanistic and therapeutic perspectives
    210. Abstract 4914: Luteolin inhibits metastasis of triple-negative breast cancer cells to the lungs
    211. Abstract 4159: Therapeutic effects of Luteolinagainst progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis
    212. EXPERIMENTAL STUDY OF ANTITUMOR AND CYTOKINES-MODULATING ACTIVITIES OF BISULFATE Luteolin AND Luteolin
    213. [Inhibitory effects of Luteolin on human gastric carcinoma xenografts in nude mice and its mechanism].
    214. Natural Polyphenols for Prevention and Treatment of Cancer
    215. 1067 POSTER Study of the Effects of Dietary Flavonoids, Luteolin and Quercetin on the Reversal of Epithelial-mesenchymal Transition in A431 Epidermal Cancer Cells
    216. Cyanidin-3-O-glucoside chloride acts synergistically with Luteolin to inhibit the growth of colon and breast carcinoma cells
    217. Synthesis of Luteolin loaded zein nanoparticles for targeted cancer therapy improving bioavailability and efficacy
    218. Growth inhibition of Luteolin on HepG2 cells is induced via p53 and Fas/Fas-ligand besides the TGF-β pathway
    219. Time-Dependent Metabolismof Luteolin by Human UDP-Glucuronosyltransferases and Its Intestinal First-Pass Glucuronidation in Mice
    220. Gas chromatographic/mass spectrometric profiling of Luteolin and its metabolites in rat urine and bile
    221. Diverse mechanisms of growth inhibition byLuteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75
    222. Hepatoprotective activity of luteolin isolated from A. millefolium on CCl4 intoxicated rat
    223. Inhibitory effects of Luteolin isolated fromixeris sonchifolia hance on the proliferation of hepg2 human hepatocellular carcinoma cells
    224. Cytotoxicity ofLuteolin in primary rat hepatocytes: the role of CYP3A‐mediated ortho‐benzoquinone metabolite formation and glutathione depletion
    225. Enhanced anticancer activity in vitroand in vivo of Luteolin incorporated into long‐circulating micelles based on DSPE‐PEG2000 and TPGS
    226. Selective Cytotoxicity of Luteolin and Kaempferol on Cancerous HepatocytesObtained from Rat Model of Hepatocellular Carcinoma: Involvement of ROS-Mediated Mitochondrial Targeting
    227. Raf and PI3K are the Molecular Targets for the Anti‐metastatic Effect ofLuteolin
    228. Study on inhibition of Luteolin on proliferation of human gastric cancer cell line BGC-823
    229. Modulation of G2/M cell cycle arrest and apoptosis by Luteolin in human colon cancer cells and xenografts
    230. Cytotoxic potential of Anisochilus carnosus (L.f.) wall and estimation of Luteolin content by HPLC
    231. Protective effects of three Luteolin derivatives on aflatoxin B1-induced genotoxicity on human blood cells
    232. In Silico Molecular Docking Studies of Rutin Compound against Apoptotic Proteins (Tumor Necrosis Factor, Caspase-3, NF-Kappa-B, P53, Collagenase, Nitric Oxide Synthase and Cytochrome C)
    233. Deciphering the molecular mechanism and apoptosis underlying the in‐vitro and in‐vivo chemotherapeutic efficacyof vanadium Luteolin complex in colon cancer
    234. Study on antitumor and antimetastatic effect of Luteolin
    235. Induction of cell cycle arrest and apoptosis inHT-29 human colon cancer cellsby the dietarycompound Luteolin
    236. Inhibitory effect of Luteolin and kaempferol on proliferation of human leukemic cell line HL-60 in vitro
    237. Luteolin suppresses tumor progression through lncRNA BANCR and its downstream TSHR/CCND1 signaling in thyroid carcinoma
    238. Luteolin enhances the cancer therapeutic effect of cisplatin in vitro and in vivo via stabilizing p53 protein
    239. Luteolin: A potential flavonoid for cancerous diseases
    240. Effect of Luteolin on glycoproteins metabolism in 1, 2-dimethylhydrazine induced experimental colon carcinogenesis.
    241. Luteolin ameliorates ferric nitrilotriacetic acid induced renal toxicity and tumor promotional response in rat
    242. In vitro study of molecular structure and cytotoxicity effect of Luteolin in the human colon carcinoma cells
    243. Abstract 1010: Synergistic antitumor effects of Luteolin and silibinin with overexpression of miR-7-1-3p inhibited autophagy and promoted apoptosis in glioblastoma
    244. 516 POSTER JNK-mediated p53 phosphorylation and stabilization contributes to the sensitization effect of Luteolin on the anti-cancer effect of cisplatin
    245. Luteolinenhances the antitumor activity of lapatinib in human breast cancer cells
    246. Evaluation of Luteolin in the Prevention of N-nitrosodiethylamine-induced Hepatocellular Carcinoma Using Animal Model System
    247. Phytochylomicron as a dual nanocarrier for liver cancer targetingof Luteolin: in vitro appraisal and pharmacodynamics
    248. Effects on Liver Lipid Metabolism of the Naturally Occurring Dietary Flavone Luteolin-7-glucoside
    249. Therapeutic and chemopreventive potential of Luteolin against growth and metastasis of breast cancer
    250. MicroRNA-6809-5p mediates Luteolin–induced anticancer effects against hepatoma by targeting flotillin 1
    251. [P8-192] High fat diet and Luteolin supplementation modulate breast tumor growth in C3H mice
    252. Anticancer activity of baicalein and Luteolin studied in colorectal adenocarcinoma LoVo cells and in drug-resistant LoVo/Dx cells
    253. Luteolin Promotes Degradation in Signal Transducer and Activator of Transcription 3 in Human Hepatoma Cells: An Implication for the Antitumor Potential of Flavonoids
    254. Flavonoids, taxifolin and Luteolin attenuate cellular melanogenesis despite increasing tyrosinase protein levels
    255. Luteolin and its inhibitory effect on tumor growthin systemic malignancies
    256. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2
    257. The molecular mechanism of Luteolin-induced apoptosis is potentially related to inhibition of angiogenesis in human pancreatic carcinoma cells
    258. Anti-tumor activities of Luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented Luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo
    259. Antioxidant and antitumor efficacy of Luteolin, a dietary flavone on benzo(a)pyrene-induced experimental lung carcinogenesis
    260. Bovine serum albumin binding, antioxidant and anticancer properties of an oxidovanadium(IV) complex with Luteolin
    261. Luteolin, a Novel Natural Inhibitor of Tumor Progression Locus 2 Serine/Threonine Kinase, Inhibits Tumor Necrosis Factor-α-Induced Cyclooxygenase-2 Expression in JB6 Mouse Epidermis Cells
    262. Luteolin enhances the bioavailability of benzo(a)pyrene in human colon carcinoma cells
    263. Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs
    264. Luteolin inhibits recruitment of monocytes and migration of Lewis lung carcinoma cells by suppressing chemokine (C–C motif) ligand 2 expression in tumor-associated macrophage
    265. Inhibition of p300 lysine acetyltransferase activity by Luteolin reduces tumor growth in head and neck squamous cell carcinoma (HNSCC) xenograft mouse model
    266. Potentiation of Luteolin cytotoxicity by flavonols fisetin and quercetin in human chronic lymphocytic leukemia cell lines
    267. Luteolin sensitizes the antiproliferative effectof interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells
    268. Induction of Endoplasmic Reticulum Stress via Reactive Oxygen Species Mediated by Luteolin in Melanoma Cells
    269. Luteolin, a novel p90 ribosomal S6 kinase inhibitor, suppresses proliferation and migration in leukemia cells
    270. Effects of Luteolinon arylamine N-acetyltransferase activity in human liver tumour cells.
    271. Evaluation of the antioxidant and anti-inflammatory nature of Luteolin in experimentally induced hepatocellular carcinoma
    272. Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats
    273. HIF‐1α/VEGF signaling‐mediated epithelial–mesenchymal transition and angiogenesis is critically involved in anti‐metastasis effect of Luteolin in melanoma cells
    274. Luteolin induces intrinsic apoptosis via inhibition of E6/E7 oncogenes and activation of extrinsic and intrinsic signaling pathways in HPV-18-associated cells
    275. Protein Kinase C Inhibition and X-Linked Inhibitor of Apoptosis Protein Degradation Contribute to the Sensitization Effect of Luteolin on Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis in Cancer Cells
    276. Synergistic anti-tumor actions of Luteolin and silibinin prevented cell migration and invasion and induced apoptosis in glioblastoma SNB19 cells and glioblastoma stem cells
    277. Natural Luteolin from Methanolic Extract of Malaysian Brucea javanica Leaves Induces Apoptosis in HeLaCell Lines
    278. Luteolin suppresses tumor proliferation through inducing apoptosisand autophagy via MAPK activation in glioma
    279. Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway
    280. Luteolinsensitizes Fas/FasL-induced apoptosis in HepG2 cellsthrough inhibiting Akt Activation and promoting XIAP Degradation
    281. Inhibitory Effect of Flavonoid Luteolin on 6-Hydroxydopamine Cytotoxicity via Suppression of Apoptosis-Related Protein Activation
    282. Luteolin induces cholangiocarcinoma cell apoptosisthrough the mitochondrial‐dependent pathway mediated by reactive oxygen species
    283. Luteolin inhibits proliferation of human glioblastoma cells via induction of cell cycle arrest and apoptosis
    284. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells
    285. Mechanism of Luteolin–induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin in HER2-overexpressing cancer cells
    286. LuteolinDecreases Epidermal Growth Factor Receptor‐Mediated Cell Proliferation and Induces Apoptosis in Glioblastoma Cell Lines
    287. Cytotoxic Effect of Luteolin on Human Colorectal Cancer Cell Line (HCT-15): Crucial Involvement of Reactive Oxygen Species
    288. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and Luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
    289. Induction apoptosis of Luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK
    290. Distinct mechanisms of DNA damage in apoptosisinduced by quercetin and Luteolin
    291. Luteolin induces myelodysplastic syndrome‑derived cell apoptosis via the p53‑dependent mitochondrial signaling pathway mediated by reactive oxygen species
    292. Effects of Luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells
    293. Luteolin sensitizes tumor necrosis factor-α-induced apoptosis in human tumor cells
    294. Induction of apoptosis by Luteolin through cleavage of Bcl-2 family in human leukemia HL-60 cells
    295. Pro-apoptotic effects of the flavonoid Luteolin in rat H4IIE cells
    296. Luteolin induced DNA damage leading to human lung squamous carcinoma CH27 cell apoptosis
    297. Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells
    298. Luteolin Inhibits Apoptosis and Improves Cardiomyocyte Contractile Function through the PI3K/Akt Pathway in Simulated Ischemia/Reperfusion
    299. Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis
    300. Flavonoid quercetin, but not apigenin or Luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants.
    301. Luteolin improves contractile function and attenuates apoptosis following ischemia–reperfusion in adult rat cardiomyocytes
    302. Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney
    303. Targeting Cell Signaling and Apoptotic Pathways by Luteolin: Cardioprotective Role in Rat Cardiomyocytes Following Ischemia/Reperfusion
    304. Induction of endoplasmic reticulum stress-mediated apoptosis and non-canonical autophagy by Luteolin in NCI-H460 lung carcinoma cells
    305. Luteolin Induces Mitochondria-dependent Apoptosis in Human Lung Adenocarcinoma Cell
    306. Luteolinsynergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism
    307. Luteolin Arrests Cell Cycling, Induces Apoptosisand Inhibits the JAK/STAT3 Pathway in Human Cholangiocarcinoma Cells
    308. Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3
    309. Luteolin Inhibits Lysophosphatidylcholine-Induced Apoptosis in Endothelial Cells by a Calcium/Mithocondrion/Caspases-Dependent Pathway
    310. Caspase Activation and Extracellular Signal‐Regulated Kinase/Akt Inhibition Were Involved in Luteolin‐Induced Apoptosis in Lewis Lung Carcinoma Cells
    311. Luteolin, an Abundant Dietary Component is a Potent Anti-leishmanial Agent that Acts by Inducing Topoisomerase II-mediated Kinetoplast DNA Cleavage Leading to Apoptosis
    312. Leishmania donovani: Intracellular ATP level regulates apoptosis-like death in Luteolin induced dyskinetoplastid cells
    313. Anti-hepatoma cells function of Luteolin through inducing apoptosis and cell cycle arrest
    314. Protective Effects of Luteolin against Apoptotic Liver Damage Induced by d-Galactosamine/Lipopolysaccharide in Mice
    315. Abstract #2672: Quercetin, Luteolin and ursolic acid are potent inducers of apoptosis in colorectal carcinoma cells: interaction with 5-Fluoracil
    316. Luteolin Induced-growth Inhibition and Apoptosisof Human Esophageal Squamous Carcinoma Cell Line Eca109 Cells in vitro
    317. Luteolin Promotes Cell Apoptosis by Inducing Autophagy in Hepatocellular Carcinoma
    318. Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis
    319. Luteolin Attenuates Foam Cell Formation and Apoptosis in Ox-LDL-Stimulated Macrophages by Enhancing Autophagy
    320. Comparative Studies to Evaluate Relative in vitro Potency of Luteolin in Inducing Cell Cycle Arrest and Apoptosis in HaCaT and A375
    321. Luteolin Induces Apoptosis via Mitochondrial Pathway and Inhibits Invasion and Migration of Oral Squamous Cell Carcinoma by Suppressing Epithelial-Mesenchymal Transition Induced Transcription Factors
    322. Luteolin‑induced protection of H2O2‑induced apoptosis in PC12 cells and the associated pathway
    323. Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma
    324. Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450
    325. Luteolin inhibits SH-SY5Y cell apoptosis through suppression of the nuclear transcription factor-κB, mitogen‑activated protein kinase and protein kinase B pathways in lipopolysaccharide-stimulated cocultured BV2 cells
    326. Induction of Apoptosis by Luteolin Involving Akt Inactivation in Human 786-O Renal Cell Carcinoma Cells
    327. Luteolin Inhibits Proliferation and Induces Apoptosis of Human Placental Choriocarcinoma Cells by Blocking the PI3K/AKT Pathway and Regulating Sterol Regulatory Element Binding Protein Activity
    328. Luteolin inhibits pyrogallol-induced apoptosis through theextracellular signal-regulated kinase signaling pathway
    329. Protective effect of Luteolin on cigarette smoke extract‑induced cellular toxicity and apoptosis in normal human bronchial epithelial cells via the Nrf2 pathway
    330. Molecular Mechanisms ofLuteolin Induced Growth Inhibition and Apoptosis of Human Osteosarcoma Cells
    331. Pyrrolidine Dithiocarbamate Inhibition of Luteolin–Induced Apoptosis through Up-regulated Phosphorylation of Akt and Caspase-9 in Human Leukemia HL-60 Cells
    332. Protective Effects of Luteolin against Amyloid β25–35-induced Toxicity on Rat Cerebral Microvascular Endothelial Cells
    333. Protective Effects of Luteolin-7-O-β-D-glucopyranoside on Hypoxic-ische mic Injury of Myocardial Cells in Neonatal Rats
    334. Luteolin Prevents H2O2-Induced Apoptosis in H9C2 Cells through Modulating Akt-P53/Mdm2 Signaling Pathway
    335. Caspase Activation and Extracellular Signal‐Regulated Kinase/Akt Inhibition Were Involved in Luteolin‐Induced Apoptosis in Lewis Lung Carcinoma Cells
    336. Luteolin Induces Apoptosis, G0/G1 Cell Cycle Growth Arrest and Mitochondrial Membrane Potential Loss in Neuroblastoma Brain Tumor Cells
    337. Luteolin–induced apoptosisthrough activation of endoplasmic reticulum stress sensors in pheochromocytoma cells
    338. Luteolin INDUCES APOPTOSIS IN AZOXYMETHANE-INDUCED COLON CARCINOGENESISTHROUGH THE INVOLVEMENT OF BCL-2, BAX AND CASPASE-3
    339. Inhibition of α-Synuclein contributes to the ameliorative effects of dietary flavonoids Luteolin on arsenite-induced apoptotic cell death in the dopaminergic PC12 cells
    340. Increase of Bax/ Bcl-XL ratio and arrest of cell cycle by Luteolin in immortalized human hepatoma cell line
    341. The Flavonoid Luteolin Increases the Resistance of Normal, but Not Malignant Keratinocytes, Against UVB-Induced Apoptosis
    342. Luteolin induces apoptosis by activating Fas signaling pathway at the receptor level in laryngeal squamous cell line Hep-2 cells
    343. Gallic Acid Induces Apoptosis via Caspase-3 and Mitochondrion-Dependent Pathways in Vitro and Suppresses Lung Xenograft Tumor Growth in Vivo
    344. Luteolinsupplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats
    345. The Flavone Luteolin Improves Central Nervous System Disordersby Different Mechanisms: A Review
    346. Luteolinprevents palmitic acid-induced hepatic steatosis by regulating ER stress in HepG2
    347. Liposome encapsulated Luteolin showed enhanced antitumor efficacy to colorectal carcinoma
    348. Protective Effect of Luteolin against β-Amyloid-induced Cell Death and Damage in BV-2 Microglial Cells
    349. Luteolin inhibits cell cycle progression andinduces apoptosis of breast cancer cellsthrough downregulation of human telomerase reverse transcriptase
    350. Luteolin modulates gene expression related to steroidogenesis, apoptosis, and stress response in rat LC540 tumor Leydig cells
    351. Luteolin Decreases EGFR-Mediated Cell Proliferation andInduces Apoptosis in Glioblastoma Cell Lines.
    352. Luteolin inhibits multi-heavy metal mixture-induced HL7702 cell apoptosisthrough downregulation of ROS-activated mitochondrial pathway
    353. Pyrrolidine Dithiocarbamate (PDTC) Attenuates Luteolin–Induced Apoptosis in Human Leukemia HL-60 Cells
    354. Effect and mechanism ofluteolin on cardiac protection and anti-apoptosis in rat cardiomyocytes with ischemia-reperfusion injury
    355. THE NATURAL FLAVONOID Luteolin INDUCES APOPTOSIS IN COLON CANCER CELLSBY DYSREGULATING THE SPHINGOLIPID RHEOSTAT
    356. The apoptosis of HepG2 cells and effect of C-jun N-terminal kinase signaling pathway induced by Luteolincombined with cisplatin
    357. Novel synthetic Luteolin analogue-caused sensitization of tumor necrosis factor-α-induced apoptosis in human tumor cells
    358. Luteolin Regulates Macrophage Polarization via the PI3K/Akt Pathway to Inhibit the Apoptosis Stimulated by Angiotensin II
    359. Luteolin Induces Apoptosis and Autophagy in Mouse Macrophage ANA-1 Cells via the Bcl-2 Pathway
    360. Stimulation of Fas/FasL‐mediated apoptosis by Luteolin through enhancement of histone H3 acetylation and c‐Jun activation in HL‐60 leukemia cells
    361. Luteolin induces caspase-dependent apoptosis via inhibiting the AKT/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells
    362. GW26-e4771 Protective and antiapoptotic effects of Luteolin on oxidative injury in H9C2 cardiomyocytes
    363. Protection of Luteolin-7-O-glucoside against apoptosis induced by hypoxia/reoxygenation through the MAPK pathways in H9c2 cells
    364. Studies on the Mechanism of Luteolin–induced Apoptosis in Breast Cancer Cell
    365. Luteolin attenuates diabetes-associated cognitive decline in rats
    366. Luteolin Ameliorates Cognitive Impairmentsby Suppressing the Expression of Inflammatory Cytokines and Enhancing Synapse-Associated Proteins GAP-43 and SYN Levels in Streptozotocin-Induced Diabetic Rats
    367. Identification of an Inhibitory Mechanism of Luteolin on the Insulin‐Like Growth Factor‐1 Ligand–Receptor Interaction
    368. Combination of Luteolin and Solifenacin Improves Urinary Dysfunction Induced by Diabetic Cystopathy in Rats
    369. Chrysin and Luteolin Attenuate Diabetes‐Induced Impairmentin Endothelial‐Dependent Relaxation: Effect on Lipid Profile, AGEs and NO Generation
    370. Protective Effects of Luteolin on Diabetic Nephropathy in STZ-Induced Diabetic Rats
    371. Luteolin reduces high glucose-mediated impairment of endothelium-dependent relaxation in rat aorta by reducing oxidative stress
    372. Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy
    373. Cardioprotective effects of luteolin on ischemia/reperfusion injury in diabetic rats are modulated by eNOS and the mitochondrial permeability transition pathway.
    374. Luteolin Limits Infarct Size and Improves Cardiac Function after Myocardium Ischemia/Reperfusion Injury in Diabetic Rats
    375. Anti-diabetic effectsof Luteolin and Luteolin-7-O-glucoside on KK-Ay mice
    376. Luteolin, a Flavone, Does Not Suppress Postprandial Glucose Absorption Through an Inhibition of α-Glucosidase Action
    377. Luteolin inhibits adipogenic differentiation by regulating PPARγ activation
    378. Effects of Luteolin 5-O-β-rutinoside in streptozotocin-induced diabetic rats
    379. Low‐dose diet supplement of a natural flavonoid, Luteolin, ameliorates diet‐induced obesity and insulin resistance in mice
    380. Luteolin inhibits inflammatory response and improves insulin sensitivityin the endothelium
    381. Effects of Luteolin on retinal oxidative stress and inflammation in diabetes
    382. Ursolic acid and Luteolin‐7‐glucoside improve lipid profiles and increase liver glycogen content through glycogen synthase kinase‐3
    383. Luteolin Attenuates Hepatic Steatosis and Insulin Resistance Through the Interplay Between the Liver and Adipose Tissue in Mice with Diet-Induced Obesity
    384. Luteolin protects against high fat diet-induced cognitive deficits in obesity mice
    385. Luteolin improves the impaired nerve functions in diabetic neuropathy: behavioral and biochemical evidences
    386. Luteolin Inhibits Hyperglycemia‐Induced Proinflammatory Cytokine Production and Its Epigenetic Mechanism in Human Monocytes
    387. Effects of Luteolin on aldose reductase,NOS system and Na~+-K~+-ATPase in cardiac muscles of early diabetes rats
    388. Luteolin enhances insulin sensitivity via activation of PPARγ transcriptional activity in adipocytes
    389. Chrysin and Luteolin Alleviate Vascular Complications Associated with Insulin Resistance Mainly Through PPAR-γ Activation
    390. Luteolin prevents uric acid-induced pancreatic β-celldysfunction
    391. Evaluation of the Wound Healing Properties of Luteolin Ointments on Excision and Incision Wound Models in Diabetic and Non-Diabetic Rats
    392. Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKα1 signalling in adipose tissue macrophages
    393. Determination of antioxidant and α-glucosidase inhibitory activities and Luteolin contents of Chrysanthemum morifolium Ramat extracts
    394. Opposite Effects of Quercetin, Luteolin, and Epigallocatechin Gallate on Insulin Sensitivity Under Normal and Inflammatory Conditions in Mice
    395. Combination Treatments with Luteolin and Fisetin Enhance Anti-Inflammatory Effects in High Glucose-Treated THP-1 CellsThrough Histone Acetyltransferase/Histone Deacetylase Regulation
    396. Protective effect of Luteolin on streptozotocin-induced diabetic renal damage in mice via the regulation of RIP140/NF-кB pathway and insulin signalling pathway
    397. Quercetin, Luteolin, and Epigallocatechin Gallate Promote Glucose Disposal in Adipocytes with Regulation of AMP-Activated Kinase and/or Sirtuin 1 Activity
    398. Luteolin protect against diabetic cardiomyopathy in rat model via regulating the AKT/GSK-3α signalling pathway
    399. [Luteolin reduces cardiac dysfunctions in streptozotocin-induced diabetic rats].
    400. Luteolin improves non-alcoholic fatty liver disease in db/db mice by inhibition of liver X receptor activation to down-regulate expression of sterol regulatory element binding protein 1c
    401. Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity
    402. The Falconoid Luteolin Mitigates the Myocardial Inflammatory Response Induced by High-Carbohydrate/High-Fat Diet in Wistar Rats
    403. Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses
    404. Anti-degenerative effect of Apigenin, Luteolin and Quercetin on human keratinocyte and chondrocyte cultures: SAR evaluation
    405. Protective effects of Luteolin on STZ-induced diabetic kidneys
    406. Structure-Activity Relationship Study Reveals Benzazepine Derivatives of Luteolin as New Aldose Reductase Inhibitors for Diabetic Cataract
    407. Wound healing effect of flavonoid rich fraction and Luteolin isolated from Martynia annua Linn. on streptozotocin induced diabetic rats
    408. The Studies on the protective effect of Luteolin on kidney in diabetic Rats
    409. Tissue Specific Action of PPARγ as a Mediator of the Metabolic Response to Flavonoid Luteolin in Diet-Induced Obesity
    410. Actions of Luteolin on Regulation of Overweight Metabolic Stressthrough the Interplay between the Liver and Adipose Tissue
    411. Effect of luteoin in delaying cataract in STZ-induced diabetic rats
    412. Luteolin Limits Infarct Size and Improves CardiacFunction after MyocardiumIschemia/Reperfusion Injury in Diabetic Rats
    413. Can Luteolin be a therapeutic molecule for both colon cancer and diabetes?
    414. Luteolin protects against high fat diet-induced cognitive deficits in obesity mice
    415. Flavonoids diosmetin and Luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes
    416. Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by Luteolin
    417. Luteolin Attenuates Hepatic Steatosis and Insulin Resistance Through the Interplay Between the Liver and Adipose Tissue in Mice with Diet-Induced Obesity
    418. Low‐dose diet supplement of a natural flavonoid, Luteolin, ameliorates diet‐induced obesity and insulin resistance in mice
    419. Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKα1 signalling in adipose tissue macrophages
    420. Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity
    421. Luteolin-Enriched Artichoke Leaf Extract Alleviates the Metabolic Syndrome in Mice with High-Fat Diet-Induced Obesity
    422. Luteolin Targets the Toll-Like Receptor Signaling Pathway in Prevention of Hepatic and Adipocyte Fibrosis and Insulin Resistance in Diet-Induced Obese Mice
    423. Luteolin Supplementation Modulates Mammary Tumor Growth in C3H Mice